Content area

|
|

Behandling af nonalkoholisk fedtleversygdom

Forfatter(e)
Sara Heebøll1, 2, Hendrik Vilstrup1 & Henning Grønbæk1 1) Medicinsk Hepatogastroenterologisk Afdeling, Aarhus Universitetshospital 2) Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital Ugeskr Læger 2018;180:V12170933
Reference: 
Ugeskr Læger 2018;180:V12170933
Blad nummer: 
Sidetal: 
2-6
Treatment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease and especially non-alcoholic steatohepatitis (NASH) and fibrosis are associated with severe liver disease and increased cardiovascular risk. It is therefore important to identify patients with NASH fibrosis. Therapeutical options include life style intervention and pharmacological treatment with vitamin E and pioglitazone; however, evidence of effect is scarce for all options. New treatments are under investigation and include glucagon-like peptide-1, farnesoid receptor as well as peroxisome proliferator-activated receptor-α/δ agonists. Bariatric surgery may be an option in selected patients.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Eskild Boeskov | 23/01
6 kommentarer
af Pal Bela Szecsi | 20/01
2 kommentarer
af Peter Søndergaard | 18/01
3 kommentarer
af Mads Henrik Koch Hansen | 16/01
2 kommentarer
af Lars Guttorm | 14/01
5 kommentarer
af Morten Ellemose Gulev | 14/01
4 kommentarer
af Henning Damgaard Laugesen | 14/01
1 Kommentar